Founder
CurrentLentitek was founded to address a significant problem facing the commercialisation of next generation therapies such as CAR-T, namely the low yields of lentiviral vector used to reprogram cells. We are developing a technology to improve the yield of lentivirus by 10 fold which can be easily integrated existing manufacturing workflows.Lentitek has already secured Scottish Enterprise funding for a proof of concept study and are now looking to prove the technology in practice by generating a CAR.